Attached files
| file | filename |
|---|---|
| 8-K - 8-K - F-star Therapeutics, Inc. | d60619d8k.htm |
| EX-3.1 - EX-3.1 - F-star Therapeutics, Inc. | d60619dex31.htm |
| EX-3.2 - EX-3.2 - F-star Therapeutics, Inc. | d60619dex32.htm |
| EX-10.1 - EX-10.1 - F-star Therapeutics, Inc. | d60619dex101.htm |
| EX-10.2 - EX-10.2 - F-star Therapeutics, Inc. | d60619dex102.htm |
| EX-10.3 - EX-10.3 - F-star Therapeutics, Inc. | d60619dex103.htm |
| EX-10.4 - EX-10.4 - F-star Therapeutics, Inc. | d60619dex104.htm |
| EX-10.5 - EX-10.5 - F-star Therapeutics, Inc. | d60619dex105.htm |
| EX-10.6 - EX-10.6 - F-star Therapeutics, Inc. | d60619dex106.htm |
| EX-10.7 - EX-10.7 - F-star Therapeutics, Inc. | d60619dex107.htm |
| EX-99.1 - EX-99.1 - F-star Therapeutics, Inc. | d60619dex991.htm |
| EX-99.2 - EX-99.2 - F-star Therapeutics, Inc. | d60619dex992.htm |
Exhibit 16.1
November 20, 2020
Securities and Exchange Commission
Washington, D.C. 20549
Commissioners:
We have read Spring Bank Pharmaceuticals, Inc.’s statements included under Item 4.01(a) of its Form 8-K filed on November 20, 2020 and we agree with such statements concerning our firm.
/s/ RSM US LLP